Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CCR8 | P51685 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357651 | 1.00 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL367648 | 0.84 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL26237923 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2356330 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2358851 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30194796 | 0.81 | — | — | |
| SCHEMBL10762482 | 0.81 | KDM4E (0.51) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28432131 | 0.81 | CHRM5 (0.53) | KDM4ECYP1A2BLMTLR7RUNX1 | |
| SCHEMBL5378152 | 0.79 | KDM4E (0.38) | KDM4ELMNACCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL5573936 | 0.78 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PFIZER INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023122093-A1 | REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | Vyera Pharmaceuticals, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-11332448-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | CHRM1, CHRM2, CHRM5 | KDM4E 2058/4885LMNA 4288/4885CCR1 2619/4885 |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | KDM4E 1342/4885LMNA 2136/4885CCR1 4429/4885 |
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PAH, PC, MPC2 | KDM4E 949/4885LMNA 1807/4885CCR1 3463/4885 |
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | KDM4E 2058/4885LMNA 4288/4885CCR1 2619/4885 |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | KDM4E 1342/4885LMNA 2136/4885CCR1 4429/4885 |
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | CAMKK1, CAMK1, CAMKK2 | KDM4E 2012/4885LMNA 3943/4885CCR1 1444/4885 |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | KDM4E 1342/4885LMNA 2136/4885CCR1 4429/4885 |
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | CBR3, HCRTR1, CYP4F11 | KDM4E 3576/4885LMNA 2373/4885CCR1 381/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | KDM4E 1086/4885LMNA 3871/4885CCR1 3293/4885 |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | KDM4E 2551/4885LMNA 1220/4885CCR1 1913/4885 |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | MRGPRX1, MRGPRX4, MRGPRX2 | KDM4E 2939/4885LMNA 4368/4885CCR1 1966/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | KDM4E 3829/4885LMNA 3865/4885CCR1 324/4885 |
| US-11524954-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | KDM4E 2058/4885LMNA 4288/4885CCR1 2619/4885 |
| US-11332448-B2 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | KDM4E 1583/4885LMNA 1612/4885CCR1 2798/4885 |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | KDM4E 2078/4885LMNA 894/4885CCR1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.